Thank you for joining us. The program will begin momentarily. - PowerPoint PPT Presentation

Thank you for joining us. The program will begin momentarily.

Management of Locally Advanced Non-Small Cell Lung Cancer Tuesday, September 15, 2020 5:00 PM – 6:00 PM ET Faculty Kelly EH Goodwin, MSN, RN, ANP-BC Heather Wakelee, MD David R Spigel, MD Elizabeth S Waxman, RN, MSN, ANP-BC Moderator Neil Love, MD

Dr Love and Faculty Encourage You to Ask Questions You may submit questions using the Zoom Chat option below Feel free to submit questions now before the program begins and throughout the program.

Familiarizing Yourself with the Zoom Interface How to answer poll questions When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.

Commercial Support This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Dr Love — Disclosures Dr Love Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

RESEARCH TO PRACTICE CME/NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Dr Goodwin — Disclosures No relevant conflicts of interest to disclose.

Dr Spigel — Disclosures Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Dracen Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Iksuda Consulting Agreements Therapeutics, Illumina, Merck, Molecular Templates, Nektar, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Seattle Genetics, Takeda Pharmaceutical Company Limited, Triptych Health Partners, TRM Oncology Aeglea BioTherapeutics, Astellas, AstraZeneca Pharmaceuticals LP, BIND Therapeutics Inc, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, G1 Therapeutics, Genentech, a member of the Roche Group, Contracted Research GRAIL, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck, Molecular Partners, Nektar, Neon Therapeutics, Novartis, Takeda Oncology, Transgene, UT Southwestern Medical Center

Dr Wakelee — Disclosures Cellworks, Daiichi Sankyo Inc, Genentech, a member of the Roche group, Helsinn Healthcare SA, INC Pharma, Janssen Biotech Inc, Consulting Agreements Merck, Mirati Therapeutics ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Contracted Research Sankyo Inc, Exelixis Inc, Genentech, a member of the Roche group, INC Pharma, Lilly, Merck, Novartis, Pfizer Inc, Xcovery

Ms Waxman — Disclosures No relevant conflicts of interest to disclose.

Management of Locally Advanced Non-Small Cell Lung Cancer Tuesday, September 15, 2020 5:00 PM – 6:00 PM ET Faculty Kelly EH Goodwin, MSN, RN, ANP-BC Heather Wakelee, MD David R Spigel, MD Elizabeth S Waxman, RN, MSN, ANP-BC Moderator Neil Love, MD

Live Webinar Faculty Heather Wakelee, MD Kelly EH Goodwin, MSN, RN, ANP-BC Professor of Medicine, Division of Oncology Thoracic Cancer Center Faculty Director Massachusetts General Hospital Stanford Cancer Clinical Trials Office Boston, Massachusetts Stanford University School of Medicine Stanford Cancer Institute Stanford, California David R Spigel, MD Chief Scientific Officer Elizabeth S Waxman, RN, MSN, ANP-BC Program Director, Lung Cancer Research Nurse Practitioner in the Department of Sarah Cannon Research Institute Thoracic/Head and Neck Medical Oncology Nashville, Tennessee The University of Texas MD Anderson Cancer Center Houston, Texas

Steering Committee Ramaswamy Govindan, MD Rasheda Persinger, NP-C Professor of Medicine Medical Oncology Lead Nurse Practitioner Director, Section of Oncology The Sidney Kimmel Comprehensive Cancer Center Anheuser-Busch Endowed Chair in at Sibley Memorial Hospital Medical Oncology Johns Hopkins Medicine Washington University School of Medicine Washington, DC St Louis, Missouri Matthew Gubens, MD, MS Associate Professor, Thoracic Medical Oncology Project Chair University of California, San Francisco Neil Love, MD Research To Practice San Francisco, California Miami, Florida Alison Holmes Tisch, MSN, RN, ANP-BC, AOCNP Clinical Operations Manager Thoracic, Neuro, Uro and Radiation Oncology Nurse Practitioner, Thoracic Oncology Stanford Health Care Palo Alto, California What Advanced Practice Professionals Need to Know: Locally Advanced Non- Small Cell Lung Cancer: Thursday, November 5, 2020, 5:00 PM to 6:00 PM ET

We Encourage Clinicians in Practice to Submit Questions You may submit questions using the Zoom Chat option below Feel free to submit questions now before the program commences and throughout the program.

Familiarizing Yourself with the Zoom Interface How to answer poll questions When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.

Management of Locally Advanced Non-Small Cell Lung Cancer Tuesday, September 15, 2020 5:00 PM – 6:00 PM ET Faculty Kelly EH Goodwin, MSN, RN, ANP-BC Heather Wakelee, MD David R Spigel, MD Elizabeth S Waxman, RN, MSN, ANP-BC Moderator Neil Love, MD

Management of Locally Advanced Non-Small Cell Lung Cancer Module 1: Use of Consolidation Durvalumab for Patients with Locally Advanced NSCLC • Overview of locally advanced NSCLC; traditional treatment paradigm • Educating patients regarding the mechanism of action and potential benefits of consolidation durvalumab • Clinical and biologic considerations for the incorporation of consolidation durvalumab in the management of locally advanced NSCLC • Practical factors surrounding the administration of consolidation durvalumab Module 2: Tolerability Considerations with Consolidation Durvalumab • Common and uncommon adverse events observed with the use of consolidation durvalumab • Counseling patients on immune-related adverse events • Management of common clinical syndromes: gastritis, pneumonitis and colitis

Management of Locally Advanced Non-Small Cell Lung Cancer Module 1: Use of Consolidation Durvalumab for Patients with Locally Advanced NSCLC • Overview of locally advanced NSCLC; traditional treatment paradigm • Educating patients regarding the mechanism of action and potential benefits of consolidation durvalumab • Clinical and biologic considerations for the incorporation of consolidation durvalumab in the management of locally advanced NSCLC • Practical factors surrounding the administration of consolidation durvalumab Module 2: Tolerability Considerations with Consolidation Durvalumab • Common and uncommon adverse events observed with the use of consolidation durvalumab • Counseling patients on immune-related adverse events • Management of common clinical syndromes: gastritis, pneumonitis and colitis

Lung Anatomy: Distribution of Lymph Nodes

Staging Regional Lymph Nodes in Lung Cancer NX Regional lymph nodes cannot be assessed N0 No regional node metastasis Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph N1 nodes and intrapulmonary nodes, including involvement by direct extension N2 Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s) Metastasis in the contralateral mediastinal, contralateral hilar, ipsilateral N3 or contralateral scalene or supraclavicular lymph node(s)

Lung Cancer Stage Grouping (AJCC 8 th Edition) Detterbeck FC et al. Chest 2017;151(1):193-203.